ADENOVECTORS FOR DELIVERY OF HEMATOPOIETIC GROWTH FACTORS AND RECEPTORS
用于输送造血生长因子和受体的腺病毒载体
基本信息
- 批准号:6355594
- 负责人:
- 金额:$ 28.77万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2000
- 资助国家:美国
- 起止时间:2000-09-01 至 2001-08-31
- 项目状态:已结题
- 来源:
- 关键词:Adenoviridae SCID mouse cell adhesion cell differentiation cell migration cytokine developmental genetics gene expression hematopoiesis hematopoietic growth factor hematopoietic stem cells immunogenetics laboratory mouse method development protein isoforms protein structure function protooncogene transfection /expression vector virus receptors
项目摘要
Adenovectors have proved highly efficient in transferring and
expressing genes in murine and human marrow stromal and endothelial
cells. At high multiplicities of infection, Ad vector expression can
be obtained in immature hematopoietic cells (CD34+) and a variety
of differentiated cell populations (erythroid, myeloid, dendritic,
megakaryocyte). In vitro and in vivo murine studies will evaluate
Ad vector delivery of cytokine genes (erythropoietin, G-CSF, GM-CSF
c-kit ligand, Flk-2 ligand), singly or in combination, for
augmentation of hematopoiesis and acceleration of recovery following
chemotherapy, radiation, or bone marrow transplantation. Mutations
at the 51 locus point to the importance of its product, the c-kit
ligand and, specifically, the transmembrane isoform (KL-2) without
a proteolytic cleavage site as important for stem cell migration,
proliferation, and differentiation, and for optimal erythropoiesis.
Soluble ligand administered systemically or produced in the Sl-Dicke
mouse cannot substitute for the transmembrane form. Transmembrane
isoforms of Flk-2 ligand may also play an important role in local
regulation of stem cell self-renewal. Transmembrane forms of c-kit
and Flk-2 ligands will be expressed by Ad vectors in stromal cells
and marrow endothelium, in vitro or by locoregional administration
in vivo, and compared to vectors expressing soluble ligand with
emphasis on improved stem cell homing, stromal/endothelial adhesion
and self-renewal. We have evidence that murine Notch expressed by
primitive hematopoietic cells, and its ligand DLL1 expressed by
stromal and endothelial cells, influence developmental fate
decisions in hematopoiesis. This will be evaluated in hematopoietic
systems where Ad vectors permit expression of high levels of Notch
or its ligand. Transient overexpression of c-kit and Flk-2 on
hematopoietic stem cells will be evaluated, and the impact on stem
cell migration, adherence. self-renewal, proliferative status, and
resistance to TGFbeta inhibition determined. Flk-l is expressed as
a very primitive hematopoietic precursor (hemoblast/hemangioblast)
that first appears in the yolk sac blood islands or their equivalent
in embryonic stem cell differentiation, but is not expressed in
later fetal or adult stem cells. We shall use Ad vectors to express
Flk-l in adult stem cells and evaluate their proliferative response
to VEGF alone or in combination with KL. Ad vector expression of the
murine ecotropic retroviral receptor will be evaluated as a method
for improving retroviral gene transduction of human stem cells.
Introduction of a marker gene (mutated nerve growth factor) and of
a methotrexate drug-resistance gene (mutated dihydrofolate
reductase) will permit evaluation of stem cell transduction
efficiency in a long-term culture assay and in vivo in SCID mice.
腺载体已被证明在转移和表达方面是高效的。
在小鼠和人骨髓基质和内皮细胞中表达基因
细胞在高感染复数下,Ad载体表达可以
在未成熟造血细胞(CD 34+)和各种
分化的细胞群体(红细胞,髓细胞,树突状细胞,
巨核细胞)。体外和体内小鼠研究将评估
细胞因子基因(促红细胞生成素、G-CSF、GM-CSF)的Ad载体递送
c-kit配体,Flk-2配体),单独或组合,用于
促进造血和加速恢复
化疗、放疗或骨髓移植。突变
在51位点,它的产品c-kit的重要性
配体,特别是跨膜同种型(KL-2),
蛋白水解切割位点对于干细胞迁移是重要的,
增殖和分化,以及最佳的红细胞生成。
全身给药或在S1-Dicke中产生的可溶性配体
小鼠不能替代跨膜形式。跨膜
Flk-2配体的同种型也可能在局部炎症中发挥重要作用,
调节干细胞自我更新。跨膜型c-kit
Flk-2配体将通过Ad载体在基质细胞中表达
和骨髓内皮细胞,体外或局部给药
在体内,并与表达可溶性配体的载体相比,
强调改善干细胞归巢、基质/内皮粘附
和自我更新我们有证据表明,小鼠Notch表达,
原始造血细胞及其配体DLL 1,
基质细胞和内皮细胞影响发育命运
造血的决定。这将在造血评估
Ad载体允许高水平Notch表达的系统
或其配体。c-kit和Flk-2的瞬时过表达在
造血干细胞将进行评估,并对干细胞的影响,
细胞迁移和粘附。自我更新,增殖状态,和
测定对TGF β抑制的抗性。Flk-1表示为
一种非常原始的造血前体(成血细胞/成血管细胞)
首先出现在卵黄囊血岛或其等价物中
在胚胎干细胞分化中,但不表达于
胚胎干细胞或成体干细胞。我们将使用Ad向量来表示
Flk-1在成体干细胞中的表达及其增殖反应
VEGF单独或与KL组合。的Ad载体表达
鼠嗜亲性逆转录病毒受体将作为一种方法进行评价,
用于改善人类干细胞的逆转录病毒基因转导。
引入标记基因(突变的神经生长因子)和
甲氨蝶呤耐药基因(突变的二氢叶酸
还原酶)将允许评估干细胞转导
在长期培养测定和在SCID小鼠体内的效率。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MALCOLM A. MOORE其他文献
MALCOLM A. MOORE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MALCOLM A. MOORE', 18)}}的其他基金
Development of SL-101, An Immunotoxin that Targets Cancer Stem Cells
开发针对癌症干细胞的免疫毒素 SL-101
- 批准号:
7219249 - 财政年份:2006
- 资助金额:
$ 28.77万 - 项目类别:
ADENOVECTORS FOR DELIVERY OF HEMATOPOIETIC GROWTH FACTORS AND RECEPTORS
用于输送造血生长因子和受体的腺病毒载体
- 批准号:
6501114 - 财政年份:2001
- 资助金额:
$ 28.77万 - 项目类别:
FACTORS INFLUENCING STEM CELL AND PLATELET PRODUCTION
影响干细胞和血小板生成的因素
- 批准号:
6490619 - 财政年份:1999
- 资助金额:
$ 28.77万 - 项目类别:
FACTORS INFLUENCING STEM CELL AND PLATELET PRODUCTION
影响干细胞和血小板生成的因素
- 批准号:
6343629 - 财政年份:1999
- 资助金额:
$ 28.77万 - 项目类别:
FACTORS INFLUENCING STEM CELL AND PLATELET PRODUCTION
影响干细胞和血小板生成的因素
- 批准号:
6139299 - 财政年份:1999
- 资助金额:
$ 28.77万 - 项目类别:
ADENOVECTORS FOR DELIVERY OF HEMATOPOIETIC GROWTH FACTORS AND RECEPTORS
用于输送造血生长因子和受体的腺病毒载体
- 批准号:
6258920 - 财政年份:1999
- 资助金额:
$ 28.77万 - 项目类别:
相似海外基金
Analysis of transmembrane proteins activity in urological cancers using humanized SCID mouse
使用人源化 SCID 小鼠分析泌尿系统癌症中的跨膜蛋白活性
- 批准号:
19K09674 - 财政年份:2019
- 资助金额:
$ 28.77万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Core B - SCID Mouse : Human Xenograft Core (Jordan Pober, MD/PhDP.I.)
核心 B - SCID 小鼠:人类异种移植核心(Jordan Pober,医学博士/博士)
- 批准号:
6756347 - 财政年份:2004
- 资助金额:
$ 28.77万 - 项目类别:
EXPERIMENTAL ANALYSIS OF VASCULER CHANGES IN CHRONIC ALLOGRAFT REJECTION USING HUMANIZED SCID MOUSE MODEL.
使用人源化 SCID 小鼠模型对慢性同种异体移植排斥中的血管变化进行实验分析。
- 批准号:
14571526 - 财政年份:2002
- 资助金额:
$ 28.77万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The heat shock protein(HSP) was investigated as the pathogenesis of focal infection with tonsil by the SCID mouse model
通过SCID小鼠模型研究热休克蛋白(HSP)作为扁桃体局灶性感染的发病机制
- 批准号:
14571629 - 财政年份:2002
- 资助金额:
$ 28.77万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Establishment of patient-like SCID mouse model by orthotopically implanting primary cultured cells from surgically-resected lung cancer tissues.
通过原位植入手术切除的肺癌组织的原代培养细胞建立类患者 SCID 小鼠模型。
- 批准号:
14571269 - 财政年份:2002
- 资助金额:
$ 28.77万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




